Key result
A 63-year-old man developed severe, debilitating anti-HMGCR necrotizing myopathy associated with atorvastatin use, requiring intensive immunosuppressive therapy without full recovery of muscle strength.
Case Report (n=1)
No
Statin-induced anti-HMGCR myopathy is a rare but potentially debilitating adverse effect that may result in persistent muscle weakness despite aggressive immunosuppressive therapy.
Alerts clinicians to persistent disability in statin-associated anti-HMGCR myopathy; single case leaves optimal immunosuppression open.
Immune-mediated necrotizing myopathy is a subtype of immune-mediated myopathy associated with or without statin use. Statins, or HMG-CoA reductase inhibitors, are the most prescribed medications for dyslipidemia. The statin-associated myopathic syndromes range from asymptomatic elevations in creatine kinase to severe debilitating muscle weakness with associated rhabdomyolysis and elevated liver enzymes. Clinical improvement occurs upon discontinuation of statins, but some patients do not recover completely. Diagnostic tests include electromyography, muscle biopsy, myositis autoantibody panel, and antibodies against the HMGCR. Here, we present a case of anti-HMGCR-related myopathy associated with atorvastatin.
No takes yet. Share an insight, caveat, or question.
Anim-Koranteng et al. (2023) conducted a case report in Anti-HMGCR myopathy (n=1). Atorvastatin was evaluated. A 63-year-old man developed severe, debilitating anti-HMGCR necrotizing myopathy associated with atorvastatin use, requiring intensive immunosuppressive therapy without full recovery of muscle strength.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: